Hubei Jumpcan Pharmaceutical Co Ltd Capital Reinvestment Ratio
Hubei Jumpcan Pharmaceutical Co Ltd capital reinvestment ratio. Hubei Jumpcan Pharmaceutical Co Ltd (600566) has a Capital Reinvestment Ratio of 0.09x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥178.57 Million) in capital expenditures (CN¥15.27 Million). Check Hubei Jumpcan Pharmaceutical Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Hubei Jumpcan Pharmaceutical Co Ltd (2000–2025)
Capital reinvestment ratio of Hubei Jumpcan Pharmaceutical Co Ltd from 2000 to 2025. This chart tracks Hubei Jumpcan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 25 annual periods. Also explore Hubei Jumpcan Pharmaceutical Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Hubei Jumpcan Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2000–2025)
Hubei Jumpcan Pharmaceutical Co Ltd capital reinvestment ratio by year from 2000 to 2025. For the full cash flow conversion analysis, see cash flow conversion of Hubei Jumpcan Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥1.20 Billion | CN¥95.86 Million | ▼ -0.1% |
| 2024 | 0.08x | CN¥2.18 Billion | CN¥174.34 Million | ▼ -8.0% |
| 2023 | 0.09x | CN¥3.46 Billion | CN¥301.64 Million | ▼ -6.3% |
| 2022 | 0.09x | CN¥2.62 Billion | CN¥243.66 Million | ▼ -29.1% |
| 2021 | 0.13x | CN¥1.89 Billion | CN¥248.32 Million | ▼ -45.6% |
| 2020 | 0.24x | CN¥1.78 Billion | CN¥429.63 Million | ▼ -5.2% |
| 2019 | 0.25x | CN¥2.15 Billion | CN¥546.44 Million | ▼ -34.9% |
| 2018 | 0.39x | CN¥1.71 Billion | CN¥668.06 Million | ▼ -37.7% |
| 2017 | 0.63x | CN¥1.19 Billion | CN¥746.25 Million | ▲ +77.2% |
| 2016 | 0.35x | CN¥913.10 Million | CN¥323.49 Million | ▼ -42.2% |
| 2015 | 0.61x | CN¥645.48 Million | CN¥395.98 Million | ▲ +25.4% |
| 2014 | 0.49x | CN¥616.11 Million | CN¥301.51 Million | ▼ -48.0% |
| 2013 | 0.94x | CN¥287.16 Million | CN¥270.10 Million | ▼ -43.1% |
| 2012 | 1.65x | CN¥27.01 Million | CN¥44.67 Million | ▼ -98.9% |
| 2011 | 147.69x | CN¥411.24K | CN¥60.74 Million | ▲ +9770.9% |
| 2010 | 1.50x | CN¥51.13 Million | CN¥76.50 Million | ▲ +2.4% |
| 2009 | 1.46x | CN¥4.92 Million | CN¥7.19 Million | ▲ +304.4% |
| 2008 | 0.36x | CN¥23.05 Million | CN¥8.33 Million | ▲ +69.4% |
| 2007 | 0.21x | CN¥36.72 Million | CN¥7.83 Million | ▼ -98.3% |
| 2006 | 12.22x | CN¥4.24 Million | CN¥51.83 Million | ▲ +1194.8% |
| 2005 | 0.94x | CN¥63.38 Million | CN¥59.80 Million | ▼ -94.7% |
| 2003 | 17.83x | CN¥2.24 Million | CN¥39.99 Million | ▲ +235.0% |
| 2002 | 5.32x | CN¥22.00 Million | CN¥117.09 Million | ▼ -55.1% |
| 2001 | 11.86x | CN¥7.43 Million | CN¥88.07 Million | ▲ +1349.6% |
| 2000 | 0.82x | CN¥23.73 Million | CN¥19.41 Million | — |